Jian Fang

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 456 citations · Full text

Medicine, Oncology, Pharmacology +17

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer

Ying Cheng, David R. Spigel, Byoung Chul Cho et al. · New England Journal of Medicine · 2024 · 275 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 258 citations

Medicine, Oncology, Pharmacology +17